Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector

Bengaluru, Karnataka, India: October 31, 2023:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced it has once again solidified its standing as a premier employer by retaining its position amongst the Top 10 Employers in the global biotech, pharma and biopharma sector, at No. 8 in 2023. This coveted recognition bestowed by the prestigious U.S.-based Science magazine underscores Biocon’s key quality attributes such as an ‘innovative leader in the industry,’ being ‘socially responsible,’ and a company with ‘loyal employees.’

Employees across Biocon and Biocon Biologics participated in the annual Top 20 Employers Survey, which Science magazine has been conducting for over a decade to identify and celebrate the finest pharma and biotech companies. Biocon’s consistent presence on the Science Top Employers list of the world’s pre-eminent pharma, biotech, and biopharma employers for 11 consecutive years underlines its standing as an employer of choice.

The Biocon Group’s patient-centric approach resonates deeply with both its employees and potential candidates, contributing to its appeal as an employer. In addition to connecting with patients, Biocon and Biocon Biologics actively engage with physicians, nurses, and pharmacists to gain insights into how it can better serve these critical stakeholders. By studying the utilization and prescription of medications, Biocon and Biocon Biologics have successfully identified opportunities to reduce wastage, enhance operational efficiency, and lower costs. This multi-faceted problem-solving approach aligns closely with the academic ethos and is highly valued by STEM job candidates.

Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics, said: “We are delighted to be recognized once again amongst the Top 10 global biotech employers. We are extremely proud of the quality of talent we have nurtured at the Biocon Group. Our people are driven by the shared purpose of enabling ‘health equity’ and are committed to develop world class biopharmaceutical products. This recognition reflects our dedication towards enabling ‘people equity’ by creating an empowering and inclusive workplace where everyone gets an opportunity to advance their careers and be recognized and rewarded for their exemplary contributions.”

 “This consistent recognition will motivate us to keep pushing the boundaries to create a highly thriving workplace culture that promotes unconventional thinking, focus on innovation, mutual respect, and collaboration. By empowering our people, we inculcate in them a strong spirit to stay the course even in the face of insurmountable challenges” she added.

In an interview with the Science magazine, Sandeep Athalye, Chief Development Officer, Biocon Biologics, said: “The purpose, vision, and patient centricity of Biocon and Biocon Biologics, resonates well with people and attracts a lot of talent. Our people are motivated to be innovative and approach the global problem of healthcare access with a lens of making medicines affordable and reachable to more people, while at the same time finding ways to make these therapies better for patients to use.”

2023 Science Careers Top Employers Survey Methodology

As has been done for several years, a white sheet describing the survey and project timeline was sent to both public relations and human resources contacts in the biotech and pharma industry in the

American Association for the Advancement of Science (AAAS) database several weeks prior to launching the online survey. This year’s web-based survey was conducted from March 1–31, 2023.

A mixed methodology was used again to recruit participants for this year’s survey. The first part of this methodology included emailed invitations to roughly 42,000 individuals who were located worldwide; these individuals were AAAS members, Science website registrants, and Science Careers registrants. The second part of the methodology included several email blasts to approximately 225 human resource (HR) contacts at industry firms and biotech/pharma advertising agencies from the Science Careers sales database.

This year, the global survey was completed by over 6,800 respondents, who came from North America (59%), Europe (18%), Asia/Pacific Rim (16%), Rest of the World (7%). Also, 36% worked in biotechnology, 40% in biopharma, 20% in pharma and 8% in others. The respondents included 28% Doctorates, 34% with a Master’s degree, 32% with a Bachelor’s degree and 6% others. In terms of gender, 52% of the respondents were male, 42% were female and 6% preferred not to respond.

About Biocon Limited: 

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Linked In: Biocon Limited; Twitter: @bioconlimited for company updates.

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, Japan.

The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics and LinkedIn: Biocon Biologics for company updates.